Related Experiment Video
Updated: Nov 29, 2025
12:25
Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
Published on: March 3, 2014
16.3K
An Update on Botulinum Toxin in Neurology
Shannon Y Chiu1, Matthew R Burns1, Irene A Malaty1
1Department of Neurology, Fixel Institute for Neurological Diseases, University of Florida, 3009 SW Williston Road, Gainesville, FL 32608, USA.
Neurologic Clinics
|November 23, 2020
Summary
Botulinum neurotoxin (BoNT) effectively treats various neurologic disorders. This review comprehensively covers its clinical uses in neurology.
Area of Science:
- Neurology
- Neuroscience
- Pharmacology
Background:
- Botulinum neurotoxin (BoNT) is a potent neuroparalytic agent.
- BoNT has established therapeutic roles in several neurological conditions.
Purpose of the Study:
- To provide a comprehensive overview of the clinical applications of BoNT in neurology.
- To summarize the current evidence supporting BoNT use for various neurologic disorders.
Main Methods:
- Literature review of clinical studies and case reports.
- Synthesis of data on BoNT efficacy and safety in neurologic treatments.
Main Results:
- BoNT is effective in managing conditions such as spasticity, dystonia, and migraine.
- Evidence supports its use in tremor, sialorrhea, and autonomic disorders.
Conclusions:
- Botulinum neurotoxin is a versatile therapeutic tool in clinical neurology.
- Continued research is expanding the scope of BoNT applications for neurologic conditions.
More Related Videos
Related Concept Videos
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
946
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
946
01:31Skeletal Muscle Relaxants: Therapeutic Uses
759
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
759
01:28Classification of Skeletal Muscle Relaxants
2.9K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
2.9K
01:29Neuromuscular Junction And Blockade
4.2K
The site of chemical communication between a motor neuron and a muscle fiber is called the neuromuscular junction (NMJ). The end of the motor neuron at the NMJ divides into a cluster of synaptic end bulbs. The cytoplasm of these bulbs consists of synaptic vesicles enclosing acetylcholine molecules, the principal neurotransmitter released at the NMJ. The region opposite the synaptic bulb that ends in the muscle fiber is called the motor end plate, which has acetylcholine receptors. Within the...
4.2K
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
2.5K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
2.5K
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
742
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
742